As per the RBI's recent annual report, fraud cases surged to 36,075 in FY24, marking a significant rise from 13,564 reported in the previou...

The guidelines recommend the use of Remdesivir for up to five days in moderate or severe cases with a high risk of progression, and only fo...

With the reporting of Omicron, a highly mutated variant of SARSCoV-2 virus and its classification as a Variant of Concern (VoC) by the Worl...

The revised guidelines continue to recommend emergency use authorization (EUA) or off-label use of remdesivir in patients with "moderate to...

The revised guidance updated on January 14 also warns of potential risk of fungal infections such as invasive mucormycosis, if anti-inflamm...

The revised guidelines continue to recommend emergency use authorization (EUA) or off-label use of remdesivir in patients with "moderate to...

Mandaviya said that the NFI 2021 would act as a guidance document for all the healthcare professionals such as clinicians, pharmacists, nur...

Indian Council for Medical Research (ICMR), the country’s leading health research body, however, has not yet revised its clinical guidance ...

Inclusion in the EUL is also important for easy international travel of Indian citizens who have been administered Covaxin.

Experts at the ICMR had been reviewing the available data and had not found any benefit. “The recovery trial document was examined and show...

No patient shall be refused admission on the ground that he/she is not able to produce a valid identity card that does not belong to the ci...

The Drug Controller General of India (DCGI) will give the final approval to both the vaccine candidates.

With some microbiologists opposing the use of HCQ for Covid-19, a debate is raging on among members of the task force over continuing with ...

In its last-issued guidance in October 2016, the WHO had restricted usage to the breakthrough drug owing to concerns around its effect on t...

Phase 3 trials are the last phase of clinical trials that a company conducts before it receives approval to market the drug here.

The stock fell 12.84 per cent to hit a 44-month low of Rs 495.55 amid weak fourth quarter results.

Emkay Research is positive on the developments and business of Nicholas Piramal Ltd though it has not made any formal rating on the stock.